發(fā)布時間：2018-08-19 12:02

【摘要】：目的觀察尼可地爾聯(lián)合瑞舒伐他汀對冠狀動脈介入治療患者心肌保護作用。方法將68例擇期進行經(jīng)皮冠狀動脈介入治療術(PCI)的冠心病患者隨機分為對照組36例和試驗組32例。對照組術前予瑞舒伐他汀10 mg,qd,共3 d;試驗組在對照組的基礎上,術前加用尼可地爾5 mg,tid,共3 d。比較2組患者臨床療效、PCI術前和術后24,48 h血清高敏肌鈣蛋白T(hs-cTnT)、超敏C反應蛋白(hs-CRP)、腫瘤壞死因子-α(TNF-α)、白細胞介素-10(IL-10)水平,以及藥物不良反應的發(fā)生情況。結果治療后,試驗組和對照組的顯效率分別為78.13%(25例/32例)和52.78%(19例/36例),差異有統(tǒng)計學意義(P0.05)。PCI術前,試驗組和對照組hs-cTnT水平分別為(36.56±15.35),(30.29±13.67)pg·mL~(-1),hs-CRP分別為(3.67±1.24),(3.53±1.32)mg·L~(-1),TNF-α分別為(6.54±2.42),(6.76±2.15)pg·mL~(-1),IL-10分別為(6.87±1.92),(7.02±1.85)pg·mL~(-1)。PCI術后24 h,試驗組和對照組hs-cTnT水平分別為(71.25±17.87),(82.65±18.34)pg·mL~(-1),hs-CRP分別為(9.48±2.35),(13.56±3.52)mg·L~(-1),TNF-α分別為(8.72±2.26),(10.65±3.16)pg·mL~(-1),IL-10分別為(13.55±4.51),(11.21±3.54)pg·mL~(-1);術后48 h試驗組和對照組hs-cTnT水平分別為(60.56±15.64),(73.54±16.51)pg·mL~(-1),hs-CRP分別為(6.62±1.98),(10.24±2.84)mg·L~(-1),TNF-α分別為(7.56±1.86),(8.86±1.95)pg·mL~(-1),IL-10分別為(11.16±3.28),(9.76±3.11)pg·mL~(-1),術后24 h與術后48 h比較,差異均有統(tǒng)計學意義(均P0.05)。試驗組及對照組均沒有出現(xiàn)明顯的藥物不良反應。結論 PCI術前尼可地爾聯(lián)合瑞舒伐他汀可以降低炎性因子,提高IL-10,減輕PCI心肌損傷,安全性好。
[Abstract]:Objective to observe the myocardial protective effect of nicoranil combined with resuvastatin on patients with coronary intervention. Methods Sixty-eight patients with (PCI) undergoing percutaneous coronary intervention were randomly divided into control group (n = 36) and trial group (n = 32). The control group was treated with resuvastatin 10 mg / g QD for 3 days, and the control group was treated with nicorandil 5 mg / d for 3 days. The clinical effects of the two groups were compared. The serum levels of Gao Min troponin T (hs-cTnT), hypersensitive C-reactive protein (hs-CRP), tumor necrosis factor- 偽 (TNF- 偽), interleukin-10 (IL-10) and adverse drug reactions were compared between the two groups. Results after treatment, the effective rates of the experimental group and the control group were 78.13% (25 / 32) and 52.78% (19 / 36), respectively. The difference was statistically significant (P0.05). 璇曢獙緇勫拰瀵圭収緇刪s-cTnT姘村鉤鍒嗗埆涓，

本文編號：2191596